
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8879311/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Outcomes of Hepatitis B Virus–Related Hepatocellular Carcinoma Patients with Undetectable Serum HBV DNA Levels. Digestive Diseases and Sciences, 2022, 67, 4565-4573.	2.3	11
2	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1.	8.2	68
3	A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil) Tj ETQq1 1 0.7	843 1245 rg B	[ /Overlock 10
4	The First Case of <i>Clostridium saudiense</i> Bacteremia in a Patient with Hepatocellular Carcinoma. Annals of Laboratory Medicine, 2022, 42, 491-493.	2.5	2
5	Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Scientific Reports, 2022, 12, 7647.	3.3	13
6	Changes in the prevalence of hepatitis B and metabolic abnormalities among young men in Korea. Korean Journal of Internal Medicine, 2022, 37, 1082-1087.	1.7	5
7	Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Digestive Diseases and Sciences, 2021, 66, 2816-2825.	2.3	5
8	Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma. Yonsei Medical Journal, 2021, 62, 12.	2.2	6
9	Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scandinavian Journal of Gastroenterology, 2021, 56, 274-280.	1.5	0
10	A comparison of factors associated with the temporal improvement in the overall survival of BCLC stage 0 hepatocellular carcinoma patients. Digestive and Liver Disease, 2021, 53, 210-215.	0.9	2
11	Outcome of patients with severe alcoholic hepatitis after Model for End-Stage Liver Disease-based allocation system implementation in Korea. Korean Journal of Transplantation, 2021, 35, 24-32.	0.1	2
12	Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease. Nutrients, 2021, 13, 1013.	4.1	18
13	The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nationâ€wide Cohort Study. Hepatology, 2021, 74, 2988-2997.	7.3	10
14	Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. Journal of Viral Hepatitis, 2021, 28, 1392-1399.	2.0	13
15	Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. Hepatology International, 2021, 15, 892-900.	4.2	15
16	Predictors and outcome of emergent Liver transplantation for patients with acute-on-chronic liver failure. Digestive and Liver Disease, 2021, 53, 1004-1010.	0.9	14
17	Impact of COVID-19 on Hepatocellular Carcinoma Management: A Multicountry and Region Study. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 1159-1167.	3.7	21
18	Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance. Clinical and Translational Gastroenterology, 2021, 12, e00290.	2.5	9

#	Article	IF	CITATIONS
19	Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea. Liver Cancer, 2021, 10, 52-62.	7.7	30
20	Incidence and risk factors for development of hepatocellular carcinoma at young age in patients with chronic hepatitis B. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	1.5	3
21	Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. Hepatology, 2020, 71, 2023-2032.	7.3	66
22	Changes in Tumor Markers and Their Implications in Selecting Liver Transplantation for Patients With Hepatocellular Carcinoma. Transplantation Proceedings, 2020, 52, 881-888.	0.6	0
23	Hepatitis B reactivation after kidney transplantation in hepatitis B surface antigenâ€negative, core antibodyâ€positive recipients. Journal of Viral Hepatitis, 2020, 27, 739-746.	2.0	8
24	Longâ€ŧerm hepatitis B surface antigen (HBsAg) kinetics during entecavir treatment in Korean patients—Functional cure unlikely. Journal of Viral Hepatitis, 2020, 27, 951-954.	2.0	5
25	Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients. Clinical and Molecular Hepatology, 2020, 26, 516-528.	8.9	42
26	Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea. Korean Journal of Internal Medicine, 2020, 35, 65-78.	1.7	11
27	Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Annals of Surgical Treatment and Research, 2020, 99, 238.	1.0	20
28	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. Korean Journal of Internal Medicine, 2020, 35, 194-204.	1.7	1
29	Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery, 2019, 23, 1559-1567.	1.7	13
30	Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma: a propensity score-matched analysis of real-world data. BMC Cancer, 2019, 19, 523.	2.6	24
31	Hepatitis B virus DNA levels and overall survival in hepatitis Bâ€related hepatocellular carcinoma patients with lowâ€level viremia. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2028-2035.	2.8	17
32	Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?. PLoS ONE, 2019, 14, e0213547.	2.5	12
33	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS ONE, 2019, 14, e0210730.	2.5	64
34	Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunology, Immunotherapy, 2019, 68, 23-32.	4.2	62
35	Novel Albumin–Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization. Digestive Diseases and Sciences, 2018, 63, 1062-1071.	2.3	23
36	Validation of the Baveno VI and the expanded Baveno VI criteria to identify patients who could avoid screening endoscopy. Liver International, 2018, 38, 1442-1448.	3.9	65

#	Article	IF	CITATIONS
37	Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?. Scandinavian Journal of Gastroenterology, 2018, 53, 727-733.	1.5	5
38	Insulin resistance and the risk of hepatocellular carcinoma in chronic hepatitis B patients. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1100-1106.	2.8	23
39	Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncolmmunology, 2017, 6, e1328335.	4.6	38
40	Liver Function Assessment Using Albumin–Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation. Digestive Diseases and Sciences, 2017, 62, 3235-3242.	2.3	44
41	Lowâ€ŀevel viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66, 335-343.	7.3	144
42	Long-term real-world entecavir therapy in treatment-naÃ <sup>-</sup> ve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response. Korean Journal of Internal Medicine, 2017, 32, 636-646.	1.7	17
43	Baracle <sup>®</sup> vs Baraclude <sup>®</sup> for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. Drug Design, Development and Therapy, 2017, Volume 11, 3145-3152.	4.3	5
44	Combination treatment with transarterial chemoembolization, radiotherapy, and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumor thrombosis: Final results of a prospective phase Il trial. Oncotarget, 2017, 8, 52651-52664.	1.8	12
45	The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE. Clinical and Molecular Hepatology, 2017, 23, 42-50.	8.9	13
46	A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut and Liver, 2017, 11, 528-534.	2.9	22
47	Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut and Liver, 2016, 10, 939-947.	2.9	15
48	Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget, 2016, 7, 47794-47807.	1.8	24
49	Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease. World Journal of Gastroenterology, 2016, 22, 3785.	3.3	15
50	Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2016, 61, 3354-3362.	2.3	13
51	The recommended treatment algorithms of the <scp>BCLC</scp> and <scp>HKLC</scp> staging systems: does following these always improve survival rates for <scp>HCC</scp> patients?. Liver International, 2016, 36, 1490-1497.	3.9	51
52	Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial. International Journal of Hyperthermia, 2016, 32, 331-338.	2.5	6
53	Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. Radiotherapy and Oncology, 2016, 118, 408-415.	0.6	38
54	Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 250-258.	8.9	42

#	Article	IF	CITATIONS
55	Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma. Clinical and Molecular Hepatology, 2016, 22, 477-486.	8.9	23
56	Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease. Gut and Liver, 2016, 10, 295.	2.9	14
57	Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. Gut and Liver, 2016, 10, 796-802.	2.9	14
58	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. Liver International, 2015, 35, 2363-2369.	3.9	21
59	Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load. Hepatology, 2015, 62, 694-701.	7.3	106
60	Enhanced Resolution of Eosinophilic Liver Abscess Associated with Toxocariasis by Albendazole Treatment. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2015, 65, 222.	0.4	6
61	Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels. Journal of Korean Medical Science, 2015, 30, 1618.	2.5	12
62	Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread. PLoS ONE, 2015, 10, e0124434.	2.5	43
63	Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 1383-1391.e6.	1.3	371
64	Hepatectomy is a reasonable option for older patients with hepatocellular carcinoma. American Journal of Surgery, 2015, 209, 391-397.	1.8	27
65	Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors. Digestive Diseases and Sciences, 2015, 60, 3794-3800.	2.3	1
66	Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: Treatment outcome and prognostic factors. Journal of Hepatology, 2015, 62, 1112-1121.	3.7	50
67	Prediction of Clinical Outcomes in Hepatitis B E Antigen Negative Chronic Hepatitis B Patients with Elevated Hepatitis B Virus DNA Levels. PLoS ONE, 2015, 10, e0144777.	2.5	5
68	Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure. Clinical and Molecular Hepatology, 2015, 21, 232.	8.9	7
69	Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein. Clinical and Molecular Hepatology, 2015, 21, 393.	8.9	4
70	Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma. Radiation Oncology Journal, 2015, 33, 217.	1.5	21
71	Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Korean Journal of Internal Medicine, 2015, 30, 32.	1.7	19
72	Relationship of Liver Stiffness and Controlled Attenuation Parameter Measured by Transient Elastography with Diabetes Mellitus in Patients with Chronic Liver Disease. Journal of Korean Medical Science, 2014, 29, 1113.	2.5	4

#	Article	IF	CITATIONS
73	High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients. Annals of Surgical Treatment and Research, 2014, 86, 256.	1.0	7
74	Can the model for end-stage liver disease score replace the indocyanine green clearance test in the selection of right hemihepatectomy in Child-Pugh class A?. Annals of Surgical Treatment and Research, 2014, 86, 122.	1.0	8
75	The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding. Clinical and Molecular Hepatology, 2014, 20, 283.	8.9	12
76	Modest alcohol consumption and carotid plaques or carotid artery stenosis in men with non-alcoholic fatty liver disease. Atherosclerosis, 2014, 234, 270-275.	0.8	29
77	Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut, 2014, 63, 1943-1950.	12.1	149
78	Single hepatocellular carcinoma ≤ cm in left lateral segment: Liver resection or radiofrequency ablation. World Journal of Gastroenterology, 2014, 20, 4059.	3.3	22
79	Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors. Gut and Liver, 2014, 8, 543-551.	2.9	15
80	Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance. Hepatology International, 2013, 7, 1010-1018.	4.2	11
81	Primary hepatic neuroendocrine carcinoma. Korean Journal of Hepato-biliary-pancreatic Surgery, 2013, 17, 34.	1.0	6
82	Ultrasonographically Detected Non-Alcoholic Fatty Liver Disease Is an Independent Predictor for Identifying Patients With Insulin Resistance in Non-Obese, Non-Diabetic Middle-Aged Asian Adults. American Journal of Gastroenterology, 2012, 107, 561-567.	0.4	104
83	Imaging features of hepatobiliary MRI and the risk of hepatocellular carcinoma development. Scandinavian Journal of Gastroenterology, 0, , 1-8.	1.5	0